A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI

Trial Details

NCT ID
NCT06368414
Phase
PHASE2
Sponsor
Korean Society of Hematology
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Asciminib
Locations (sample)
  • Incheon, Incheon, South Korea|37.45646,126.70515

Key Eligibility Criteria

  • 19 year or older
  • CP-CML patients who are taking current TKIs (imatinib, nilotinib or dasatinib) for 5 years or more
  • Patients who have failed maintaining MR3.0 after 1 or more cessation trial of TKIs.
  • Patients who regained MR3.0 or deeper molecular response by TKIs retrial after TKI cessation failure at the time of screening

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →